Skip to main content
Funded Studies

Gergely Toth, PhD

Chief Executive Officer at Cantabio Pharmaceuticals

Location: Palo Alto, CA United States

Gergely Tóth is the CEO and founder of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the School of Pharmacy at University College London as a Honorary Lecturer and with the Research Center for Natural Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a business professional with a long-term focus on developing therapeutics for neurodegenerative diseases. Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he pursued drug discovery research for Parkinson’s and Alzheimer’s diseases.

Dr. Tóth received his doctorate from the Department of Biomedical Sciences at Creighton University. He is also a graduate of the executive MBA program at the Judge Business School, University of Cambridge. He was a postdoctoral fellow at the Department of Molecular Biology at the University of California at Berkeley in 2001. 


Associated Grants

  • Developing Assays to Quantify Cys106 of DJ-1 in Distinct Oxidized States as a Potential Diagnostic Tool for Parkinson’s Disease

    2020


  • Determination of the 3D Structure of Biologically Active Small Molecules in Complex with DJ-1

    2013


  • Identification of Small-molecule Stabilizers of DJ-1: Biophysical and Cellular Validation

    2010


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.